The UK government has committed GBP 580 million to building a state-of-the-art biological defence lab and infrastructure modernisation at Porton Down. Official announcements have been scant on detail, other than noting that the new lab will form part of ‘Project Andromeda’. Here’s what we know about it so far.
Buried within the tide of UK defence budget pronouncements around the time of the Defence Investment Plan’s publication was the June 2026 announcement that a sum of around GBP 580 million out to April 2030 will be devoted to construction and development of a new biological defence laboratory, at the UK government’s Porton Down complex in Wiltshire.
Dstl (Defence Science and Technology Laboratory) is the primary research and development arm of the UK Ministry of Defence (MoD). Dstl (and its prior incarnation DERA) has long operated chemical and biological defence research activities at Porton Down and, in the past, ran the now-abandoned UK’s offensive chemical and biological research from that complex.
Although the phrase ‘Porton Down’ is often used synonymously with regard to secretive defence research against chemical and biological weapons, it is important to note that non-defence health and medical research activities, such as the UK Health Security Agency are also located at Porton Down. In some circles, ‘Porton Down’ is a rapid-access lane into conspiracy thinking. But real work necessary to the UK’s defence and health happens there.
One can easily be permitted two observations at this point. First, GBP 580 million is a lot of money and taxpayers could be forgiven for wanting to know what it is being spent on. Second, actual details on the proposed expenditures are scant at present. Even by current standards, official announcements have been largely devoid of granularity. The new laboratory complex is part of something called ‘Project Andromeda’ and will be named after Ernest Bevin, the post-WW2 UK Foreign Secretary and early exponent of NATO.
It is no secret among people in the CBRN defence community that many of the facilities at the venerable Porton Down complex are showing their age. Entire countries have risen and fallen during the tenure of UK CBRN defence at the site. Given the general decline in UK defence spending over previous decades and general underinvestment in CBRN defence, there are many things that, conceivably, could absorb half a billion pounds or more at Porton Down.
Aside from a 2022 feasibility study awarded to UK firm Jacobs UK Ltd and a single mention in Parliament, searches for ‘Project Andromeda’ hit a blank wall. The UK MoD written answer in Parliament shows that this project is very much in the early days. Per Luke Pollard MP, Minister of State for Defence Readiness and Industry:
“The Ernest Bevin Building forms part of Project Andromeda within the National Biosecurity Centre programme at Porton Down. The project is currently scheduled to enter the concept design phase in FY 2027-28, with construction forecast to commence thereafter with the new facility being completed in the late. These dates are indicative and remain subject to the ongoing development of the programme in its initial phase.”
But what will the GBP 580 million actually be spent on? Hints in specialist publications are sparse, but a few exist.
Because we are talking specifically about biological defence, the need to safely handle samples of dangerous biological pathogens is part of the bundle.
Specialist publication Lab Design News speaks at some length about mechanical, air-handling, electrical, physical security, and data security factors that increase the complexity and expense of such laboratories. Many biological warfare threats that would need to be investigated need to be handled under Biological Safety Level (BSL) BSL 3 and some at BSL 4. The architectural design and engineering effort needed to achieve and maintain these levels of certification is not cheap and comes from specialist contractors that charge a premium.
Some comparison is relevant. New BSL-4 facilities are rare. This correspondent was fortunate to visit the much smaller Spiez Laboratory BSL-4 facility in Switzerland during 2012, when it was commissioned. Open-source research hints that Swiss facility was a small fraction of GBP 580 million in expense, but it is a much smaller footprint facility built some years ago. It is also possible that some of the expense may involve safe decommissioning of older facilities on the Porton Complex or moving some functions to a new building, but this remains speculation.
Construction itself will account for some of this expense, with the necessary additional overheads of performing the work on one of the UK government’s most secure complexes. This would be the case even with a regular office building. But with biosecurity laboratories, BSL-3 and BSL-4 specialist HVAC (heating, ventilation, and air conditioning) and plumbing expenses often account for as much as half or even 60% of the construction costs (data on cost per square metre on cleanrooms to BSL-3 standard is prolific online).
Security provisions, emergency decontamination, fire safety, and the likely need to store and handle cryogenic liquids needed for some processes and procedures will increase overall expenses relative to a generic biotech sector building.
Then there is the issue of instrumentation. Given the 5 or more years of the construction timeline, it would be futile for the UK government to commit to a specific equipment set, given the rate at which scientific instrumentation in chemical and biological analytical equipment is improving. The budgetary allocations are almost certainly vague here, rather than specifying particular bits of kit.
In some fast-moving areas of microbiology and molecular chemistry, 5 years is two generations of equipment. Five years can also represent a huge shift in price in some areas of technology. Indeed, I would be very suspicious of any specific details on fitting out the Bevin lab at this point in time. There are, likely, generic budget items for broad categories of instrumentation right now, based on estimates and headroom for changes.
We can estimate the broader categories of things that will go into such a laboratory, even if specific end-items would be difficult to predict with granularity. These would likely include, but not be limited to high end electron microscopes, numerous varieties of DNA-sequencing equipment, mass spectrometry, gas chromatography, nuclear magnetic resonance systems, and various advanced imaging technologies are only the start.
Despite the size of this project, it is dwarfed by the world’s pharmaceutical and biotechnology industries, who drive the development of laboratory instrumentation. Procurement details will likely be opaque for some time to come, however, given the early stage of the project.
